Lantheus Holdings, Inc. (NASDAQ: LNTH) is considered one of the cheap healthcare stocks to buy heading into 2026, with a ‘Buy’ rating from 80% of analysts and a median price target of $75, indicating an 18.48% upside potential. Jefferies analyst Matthew Taylor maintains a Buy rating with a $105 price target for LNTH, suggesting a 66% upside. Leerink Partners recently lowered their price target on LNTH to $90 from $97 due to 340B pricing pressures and competitive dynamics affecting the Pylarify franchise. LNTH reported mixed financial results for the third quarter, with revenue exceeding estimates by 5%, but diluted EPS falling short by 2% due to lower Pylarify revenues impacted by pricing pressures. Established in 1956, LNTH is a Massachusetts-based company specializing in diagnostic and therapeutic products for various diseases. While LNTH shows promise as an investment, other AI stocks may offer greater upside potential and lower downside risk. For investors seeking undervalued AI stocks with potential benefits from Trump-era tariffs and onshoring trends, a free report on the best short-term AI stock is available.

Read more at Yahoo Finance: Wall Street Remains Bullish On Lantheus Holdings, Inc. (LNTH)